|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
3
|
Resverlogix Corp.
|
Sep 07, 2017 01:45PM
|
|
Re: Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink
|
6
|
Resverlogix Corp.
|
Dec 04, 2017 11:34AM
|
|
Re: Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink
|
5
|
Resverlogix Corp.
|
Dec 04, 2017 11:38AM
|
|
Re: Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink
|
4
|
Resverlogix Corp.
|
Dec 04, 2017 11:55AM
|
|
Re: Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink
|
1
|
Resverlogix Corp.
|
Dec 04, 2017 01:45PM
|
|
Re: Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink
|
2
|
Resverlogix Corp.
|
Dec 04, 2017 03:22PM
|
|
Re: Resverlogix Confirms Interim Filings on SEDAR
|
1
|
Resverlogix Corp.
|
Oct 03, 2020 02:29PM
|
|
Re: RESVERLOGIX CORP WTS 2021
|
3
|
Resverlogix Corp.
|
May 11, 2021 05:55PM
|
|
Re: Resverlogix H2 2018 events
|
6
|
Resverlogix Corp.
|
Aug 29, 2018 12:53AM
|
|
Re: Resverlogix H2 2018 events
|
4
|
Resverlogix Corp.
|
Sep 30, 2018 03:29AM
|
|
Re: Resverlogix now listed as a Presenting Company at Biopharm America
|
2
|
Resverlogix Corp.
|
Sep 22, 2017 11:34AM
|
|
Re: Resverlogix now listed as a Presenting Company at Biopharm America
|
2
|
Resverlogix Corp.
|
Sep 22, 2017 02:16PM
|
|
Re: Resverlogix Publications, Presentations and Abstracts
|
2
|
Resverlogix Corp.
|
Sep 27, 2017 10:19AM
|
|
Re: Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
|
4
|
Resverlogix Corp.
|
Aug 23, 2022 05:21PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
10
|
Resverlogix Corp.
|
Jun 22, 2020 12:02PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
6
|
Resverlogix Corp.
|
Jun 22, 2020 12:29PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
2
|
Resverlogix Corp.
|
Jun 22, 2020 06:09PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
5
|
Resverlogix Corp.
|
Jun 22, 2020 08:46PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
3
|
Resverlogix Corp.
|
Jun 22, 2020 09:00PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
2
|
Resverlogix Corp.
|
Jun 23, 2020 02:22AM
|
